deltatrials
Completed PHASE2 NCT00004127

Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach

A Phase II Study of Oxaliplatin in Combination With Fluorouracil and Leucovorin in Carcinoma of the Esophagus and Gastric Cardia

Sponsor: National Cancer Institute (NCI)

Conditions Esophageal Cancer Gastric Cancer
Interventions FOLFOX regimen fluorouracil leucovorin calcium oxaliplatin
Updated 6 times since 2017 Last updated: Feb 8, 2013 Started: Feb 29, 2000 Primary completion: Oct 31, 2002 Completion: Aug 31, 2003

Listed as NCT00004127, this PHASE2 trial focuses on Esophageal Cancer and Gastric Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Feb 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • University of Chicago
Data source: University of Chicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States, Buffalo, United States, Chicago, United States, Cleveland, United States, Columbus, United States, Decatur, United States, Evanston, United States, Fort Wayne, United States, Greenville, United States, Harvey, United States and 10 more location s